Literature DB >> 28881914

Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines.

S Roselló1, I Blasco1, L García Fabregat1, A Cervantes1, K Jordan2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28881914     DOI： 10.1093/annonc/mdx216

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  21 in total

Review 1.  Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.

Authors:  Cristina Gutierrez; Colleen McEvoy; Laveena Munshi; R Scott Stephens; Michael E Detsky; Joseph L Nates; Stephen M Pastores
Journal:  Crit Care Med       Date:  2020-01       Impact factor: 7.598

2.  Pre-medication protocols for the prevention of paclitaxel-induced infusion related reactions: a systematic review and meta-analysis.

Authors:  Samuel Dubinsky; Deep Patel; Xiang Wang; Amirrtha Srikanthan; Terry L Ng; Corey Tsang
Journal:  Support Care Cancer       Date:  2022-02-12       Impact factor: 3.603

3.  Beyond the Classroom: An Observational Study to Assess Student Pharmacists' Confidence and Perception of a High-Fidelity Manikin Chemotherapy Infusion Reaction Simulation.

Authors:  Jeremiah K Jessee; Akera Miller; Alex M Ebied
Journal:  J Pharm Technol       Date:  2022-01-26

4.  First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Authors:  Debbie Robbrecht; Christiane Jungels; Morten Mau Sorensen; Iben Spanggaard; Ferry Eskens; Signe Ø Fretland; Tormod Kyrre Guren; Philippe Aftimos; David Liberg; Christer Svedman; Lars Thorsson; Neeltje Steeghs; Ahmad Awada
Journal:  Br J Cancer       Date:  2021-12-13       Impact factor: 9.075

5.  Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers.

Authors:  Emi Goto; Toshifumi Yamaguchi; Nobuhiro Hattori; Masahiro Goto; Masami Nishihara; Kazuhisa Uchiyama; Yoshiyuki Rikitake
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 6.  Adverse Events of Oncologic Immunotherapy and Their Management.

Authors:  Fedricker Diane Barber
Journal:  Asia Pac J Oncol Nurs       Date:  2019 Jul-Sep

7.  PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies.

Authors:  Yaelle Bavli; Bing-Mae Chen; Steve R Roffler; Marina A Dobrovolskaia; Eldad Elnekave; Shifra Ash; Yechezkel Barenholz; Keren Turjeman
Journal:  Molecules       Date:  2020-01-28       Impact factor: 4.411

8.  Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.

Authors:  Hanfei Guo; Wenqian Li; Lei Qian; Jiuwei Cui
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

9.  Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.

Authors:  Barry W Neun; Yechezkel Barenholz; Janos Szebeni; Marina A Dobrovolskaia
Journal:  Molecules       Date:  2018-07-12       Impact factor: 4.411

Review 10.  Roadmap and strategy for overcoming infusion reactions to nanomedicines.

Authors:  Janos Szebeni; Dmitri Simberg; África González-Fernández; Yechezkel Barenholz; Marina A Dobrovolskaia
Journal:  Nat Nanotechnol       Date:  2018-10-22       Impact factor: 39.213
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.